Urinary incontinence in males — types, epidemiology, pathogenesis, risk factors, screening, evaluation and management

15–20% of men above 65 years have some degree of urinary incontinence — roughly half the female rate, but rising steeply with age, frailty and institutionalisation.

OAB symptoms are reported by about 40% of men aged ≥75, most of whom also have urgency incontinence.

Male incontinence in nursing homes is common and men managed with chronic catheters are at particularly high risk of symptomatic infection.

Urgency incontinence / OAB — commonest type in older men; usually secondary to detrusor overactivity from bladder outlet obstruction, stroke, Parkinson's disease or dementia.

Overflow incontinence from incomplete emptying — the characteristically "male" type: benign prostatic obstruction, urethral stricture, or an acontractile bladder from diabetic neuropathy.

Stress incontinence — unusual in men and almost always iatrogenic: after transurethral surgery, radical prostatectomy or pelvic radiotherapy damaging the sphincter.

Functional incontinence — dementia, stroke, immobility, restraints, inaccessible toilet.

Mixed patterns and DHIC (detrusor overactivity with impaired contractility) are frequent in the very old male and explain why antimuscarinics can precipitate retention.

Post-micturition dribble — a distinct, benign symptom from bulbar urethral pooling, treated by urethral milking, not by drugs.

Normal continence in the male depends on parasympathetic (nervi erigentes, S2–S4) detrusor contraction, sympathetic (hypogastric, T11–L2) bladder relaxation and bladder-neck/urethral α-adrenergic contraction, and somatic (pudendal) external sphincter control, coordinated at the sacral micturition centre under cortical inhibition.

Prostatic enlargement raises outlet resistance → detrusor hypertrophy, collagen deposition, loss of compliance and secondary detrusor overactivity → urgency and frequency; later, detrusor decompensation → high residual urine and overflow.

Ageing changes — reduced bladder capacity, higher residual volume, more involuntary contractions, altered receptor profile with M3 receptors functionally dominant, and loss of nocturnal vasopressin rhythm with raised ANP causing nocturnal polyuria.

Neurological disease: stroke — detrusor hyperreflexia in ~68–82%, detrusor–sphincter dyssynergia in ~14%, and incontinence in the acute phase is a powerful predictor of poor outcome. Parkinson's disease — detrusor hyperreflexia in up to 79%, mimicking BPH; multiple system atrophy adds sphincter dyssynergia.

Sphincter injury after prostatic surgery or radiotherapy produces true stress incontinence with intrinsic sphincter deficiency.

Age; benign prostatic enlargement and LUTS; prostate surgery or radiotherapy; neurological disease (stroke, Parkinson's, dementia, cord lesion, multiple sclerosis); diabetes mellitus (neuropathic bladder, osmotic diuresis); obesity and metabolic syndrome; immobility and frailty; constipation and faecal impaction; polypharmacy (anticholinergics, opioids, diuretics, sedatives, α-agonists, calcium-channel blockers, SGLT-2 inhibitors); alcohol and caffeine; chronic catheterisation.

Case-finding is essential — men under-report because of embarrassment. Use the three standard questions on bladder trouble, involuntary loss and pad use as part of every comprehensive geriatric assessment and in every long-term care admission.

Quantify symptoms with the IPSS / AUA Symptom Index (seven items, each 0–5: mild 0–7, moderate 8–19, severe 20–35) plus the single quality-of-life question — this is the standard screening instrument in men.

Basic evaluation: focused history with bladder diary, targeted examination including digital rectal examination (size, consistency, nodules, sphincter tone) and neurological assessment, urinalysis, and post-void residual.

Clean urine sample in a frequently incontinent man can be obtained through a condom catheter after cleaning the penis.

Uroflowmetry is a valuable non-invasive screen: Qmax <10 mL/s on a voided volume >150 mL indicates obstruction or impaired contractility.

Selected tests: serum creatinine (mg/dL) and renal ultrasound if retention or hydronephrosis is suspected; blood glucose (mg/dL) and calcium (mg/dL) for polyuria; PSA (ng/mL) after shared decision-making where life expectancy exceeds 10 years; urine cytology and cystoscopy for haematuria or new irritative symptoms in a smoker; multichannel urodynamics in neurological disease, prior failed surgery, or before considering prostatic surgery in an equivocal case.

Reverse the reversible (DRIP), then match treatment to type.

Behavioural therapy — pelvic floor muscle training (also effective for post-prostatectomy stress leak), bladder training, timed voiding, fluid and caffeine modification, double voiding, and urethral milking for post-micturition dribble. Combined behavioural plus drug therapy is superior to either alone in men with OAB.

Drugs: α-blocker (tamsulosin 0.4 mg, alfuzosin 10 mg, silodosin 4 mg) for obstruction-related symptoms — watch postural hypotension and falls; add a 5-α-reductase inhibitor if prostate volume exceeds 30–40 mL; add an antimuscarinic or a β3-agonist for persistent storage symptoms provided PVR is not elevated.

Surgery: TURP or laser enucleation for obstruction with retention, renal impairment, recurrent UTI, stones or gross haematuria; artificial urinary sphincter or male sling for post-prostatectomy stress incontinence; intradetrusor botulinum toxin or sacral neuromodulation for refractory OAB.

Containment when cure is not possible: external (condom) catheter only in a dependent man without retention, absorbent products, and intermittent catheterisation for chronic retention; chronic indwelling catheters only for defined indications.

Vibegron (Gemtesa) approved December 2024 for men with OAB symptoms already receiving pharmacological therapy for BPH — the first β3-agonist with this specific indication, based on the phase-3 COURAGE (URO-901-3005) trial in ~1100 men showing significant reduction in micturitions, urgency episodes, nocturia and urgency incontinence with low retention risk.

AUA/GURS/SUFU Incontinence after Prostate Treatment Guideline (2024) standardises evaluation and management of post-prostatectomy incontinence, reaffirming the artificial urinary sphincter as the definitive option for significant stress leak and reserving slings for mild-to-moderate leak.

AUA/SUFU OAB Guideline 2024 recommends β3-agonists preferentially in older men, mandates PVR before advanced therapy in men with an enlarged prostate, and integrates frailty assessment into decision-making.

AUA LUTS/BPH Guideline (2023 amendment, expanded 2026) reframes management around bladder function preservation and shared decision-making rather than a fixed treatment ladder, and formally includes minimally invasive surgical therapies and prostatic artery embolisation.

Indian context: LASI analyses show older Indian men with type 2 diabetes carry the highest burden of incontinence among urological disorders, ahead of stones and prostate disease — making glycaemic control an incontinence intervention in Indian practice. NPHCE district geriatric units and AB-PMJAY (with the Ayushman Vay Vandana Card for those aged 70+) now cover prostatic surgery and continence services.

Key contrast to write down: in women the commonest type is stress/mixed; in men it is urgency and overflow, with stress being almost always post-surgical. Examiners look for this line.

Numbers: 15–20% prevalence >65 y; OAB symptoms ~40% at ≥75 y; IPSS 0–7 mild / 8–19 moderate / 20–35 severe; Qmax <10 mL/s abnormal on volume >150 mL; prostate >30–40 mL justifies a 5-ARI; 5-ARI takes 3–6 months to act.

Mnemonic for male UI causes — "PROSTATE": Prostatic obstruction · Radiotherapy/ Radical prostatectomy · Overactive bladder · Stricture · Tumour (bladder/prostate) · Autonomic neuropathy (diabetes) · Toxins/drugs · Environment and function.

Always measure PVR before an antimuscarinic in a man — this single step prevents iatrogenic retention and is a reliable mark-earner. Examiner traps — (1) Do not attribute all male LUTS to the prostate; stroke, Parkinson's and diabetes are common and treatable contributors. (2) Do not give an antimuscarinic without knowing the PVR. (3) Do not use a condom catheter in a man with retention. (4) Do not order PSA during an acute male UTI — it needs about 6 months to return to baseline. (5) Do not forget post-micturition dribble as a separate, drug-resistant entity.

15–20% of men over 65 are incontinent; urgency and overflow dominate.

Stress incontinence in a man is iatrogenic until proved otherwise.

IPSS: mild 0–7, moderate 8–19, severe 20–35.

Qmax <10 mL/s on a void of >150 mL suggests obstruction or poor contractility.

DHIC explains why an antimuscarinic can tip an old man into retention.

Combined behavioural + drug therapy beats either alone in male OAB.

Vibegron (2024) is the first β3-agonist licensed for men with OAB on BPH therapy.

Artificial urinary sphincter is the definitive treatment for severe post-prostatectomy stress incontinence.